Letter 1

Professional Experience with Functional Genomic Analysis (FGA)

Morgan Clark Camp, MD · Functional and Integrative Medicine · July 9, 2026

To: Physicians, regulators, and prospective partners evaluating Functional Genomic Analysis (FGA)
Subject: My use of the FGA platform and professional experience with the work of Robert (“Bob”) Miller (CTN)

I am Morgan Clark Camp, a physician with more than twenty years of clinical experience in functional and integrative medicine. I am writing to offer a candid, clinical perspective on the Functional Genomic Analysis (FGA) software platform. I have used FGA extensively—on myself, my family, and most of my patients—and I am willing to sign this letter under my name and license. I understand that the platform faces criticism when entering new markets, so I want to state precisely what FGA is and is not, and why I believe it qualifies as an adjunct to conventional medical care.

First, let me be clear about how I use it, because this addresses many criticisms I have heard. FGA is not a diagnostic device, and I do not use it as one. It is a decision-support and educational tool that organizes a patient’s raw genetic data into functionally meaningful biochemical pathways to help me generate hypotheses; I then test or refute those hypotheses using the standard history, physical examination, laboratory testing, and clinical judgment. Criticisms claiming the software “diagnoses disease” or “replaces doctors” are aimed at claims responsible users do not actually make.

1. How FGA helps me identify factors that may contribute to disease

FGA reads a patient’s raw single-nucleotide polymorphism (SNP) data and organizes thousands of variants into functionally related pathways, including methylation and transsulfuration, oxidative stress and antioxidant capacity, iron and heme metabolism, neurotransmitter synthesis, nitric oxide chemistry, and detoxification. Instead of reading individual variants in isolation, I can see how multiple variants with smaller individual effects converge within the same pathways and collectively produce effects that may be clinically meaningful. This pathway-based perspective has pointed me toward factors I might otherwise have missed on several occasions. Crucially, the software surfaces testable hypotheses; patient improvement comes from the clinical actions taken afterward with laboratory data and symptoms, not from the report itself.

2. Why I believe FGA is grounded in sound scientific principles

The underlying premise—that genetic variants can alter enzyme function, nutrient requirements, and susceptibility to environmental exposures—is not controversial. It is foundational to two well-established scientific fields: pharmacogenomics and nutrigenomics. FGA frequently surfaces relationships that appear in textbooks, for example:

• G6PD deficiency: a well-studied X-linked enzyme deficiency. Oxidative stressors such as high-dose intravenous vitamin C and ozone/oxidative therapies may trigger hemolysis. Identifying this risk before treatment is prudent standard care, not an edge-case practice.
• HFE-related hereditary hemochromatosis: established variants (C282Y, H63D) increase susceptibility to iron overload, which can then cause tissue oxidative damage, joint pain, and inflammation.
• BH4（tetrahydrobiopterin）metabolism：BH4 is an essential cofactor for aromatic amino acid hydroxylases (involved in phenylalanine, tyrosine, and tryptophan) and nitric oxide synthase; related disturbances may affect both neurotransmitter synthesis and chemical processes involved in detoxification.

I carefully distinguish between what is well established—such as the single-gene-to-enzyme relationships mentioned above—and what is still developing: some of the integrated, multi-pathway explanations FGA proposes remain hypotheses and have not yet been fully validated by formal research. The strength of this tool is that it presents both categories; a competent clinician can distinguish between them and act accordingly.

3. How FGA differs from other tools I have used

Most consumer and clinical genetic reports provide isolated variants or single-gene risk scores. FGA differs in three ways. First, it organizes information by biochemical pathways and by the converging, cumulative effects of variants rather than analyzing SNPs one by one; the platform’s “pyramid” model is built on this approach. Second, it explicitly integrates environmental and toxic exposure burden with genetic susceptibility, which aligns with how chronic disease manifests clinically. Third, an active research community and a global practitioner network continually refine the platform, so the interpretive framework advances with new findings rather than staying static. I have not found another tool that combines pathway-level integration, environmental context, and this pace of updates.

4. Why FGA should serve as an adjunct to medical care, not a substitute

FGA’s own materials clearly state that the analysis does not diagnose disease; it organizes data, evaluates functional disturbances, and supports nutrition plans. That is exactly how I use it: alongside standard assessments, never in place of them. Genetic variants indicate tendencies, not destinies; they must be interpreted together with laboratory results, medical history, and examinations. Used in this way, FGA makes my care more individualized; for findings such as G6PD, it also makes care markedly safer because it can flag interventions to avoid before harm occurs. An adjunct that both enhances individualization and helps prevent harm reflects precisely the goals of precision medicine.

5. What I gain from the biweekly seminars and ongoing research

Bob hosts a practitioner webinar every other week, and I find it valuable in several ways. The sessions transparently introduce emerging ideas and label them as hypotheses rather than settled conclusions; they explain foundational biochemistry—including iron and heme metabolism, NADPH oxidase and oxidative stress, mast cells and inflammatory signaling, and methylation—at a clinically usable depth; and they invite critique from the global clinical community, which is how a framework should be tested and refined. The NutriGenetic Research Institute has presented research at international scientific conferences, including ILADS, reflecting a willingness to have these ideas examined by peers. I use this as a source of testable ideas, and the materials are provided in that manner.

6. On Bob Miller's Ability to “Connect the Dots”

I know that some criticism is directed personally at Bob, so I want to respond directly. Bob is a systems thinker in the truest sense. His particular gift is seeing how multiple small genetic and environmental factors converge to create a clinical picture that no single variable can explain, and then building a coherent, teachable framework from that. Some of these connections run ahead of formal evidence. Bob is candid about this, and so am I. Being ahead of the evidence is not the same as being wrong; much of medical progress begins with reasoned hypotheses that are later formally proven. The responsible approach—one Bob models and teaches—is to treat these connections as hypotheses, test them clinically, and discard what fails to hold up. In two decades of practice, I have found his pattern recognition to be unusually illuminating, often steering me toward answers I would not have reached on my own.

7. Clinical Examples

The case I can present with the greatest transparency is my own, because there is no issue of patient identity.

My own experience: for years, I was unusually sensitive to exposure to jet fuel and petrochemical products, along with persistent fatigue and low mood. FGA identified variants affecting my ability to regenerate BH4. Because BH4 participates in neurotransmitter synthesis, nitric oxide production, and detoxification-related chemistry, this offered a coherent mechanistic explanation for a set of symptoms that had previously been hard to connect. Targeted cofactor support produced meaningful improvements in my energy, mood, and tolerance to chemical exposures. I present the underlying biochemical relationships as established knowledge, while reporting my response as a personal clinical experience.

• G6PD deficiency: FGA flagged G6PD deficiency and immediately changed my treatment options in a concrete way. I now avoid high-dose vitamin C and ozone/oxidative therapies I might otherwise have used, because hemolysis can occur in G6PD-deficient individuals receiving these treatments. The software identified a real safety concern before harm occurred.
• HFE/hemochromatosis: FGA identified HFE variants associated with iron overload. Excess iron can drive oxidative stress and inflammation; after I addressed my iron status, a longstanding burden of pain and inflammation—never previously linked to iron—resolved completely.

Since then, I have applied the same analysis to family members, including my parents, and to roughly ninety percent of my patients, observing similar patterns: FGA repeatedly surfaces factors that can shift the direction of care. The following anonymized cases represent these experiences.

Case A—Avoiding Unsafe Treatment (G6PD): A middle-aged patient with fatigue would have likely received high-dose intravenous vitamin C under common integrative medicine protocols. The FGA indicated G6PD deficiency, which was subsequently confirmed by enzyme testing. We removed high-dose vitamin C and oxidative therapies from the protocol, avoiding potential hemolytic reactions, and adopted a milder antioxidant strategy; the patient’s symptoms improved without adverse events.

Case B—Iron Overload (HFE): A patient with joint pain, fatigue, and “unexplained” inflammation showed HFE variants on the FGA; ferritin and transferrin saturation tests confirmed iron overload. After implementing appropriate iron reduction strategies and targeted support, pain and inflammation markers improved significantly.

Case C—Mood and Chemical Sensitivity (BH4 / Methylation): A patient with treatment-resistant low mood and sensitivity to multiple chemicals had converging variants in BH4 recycling and methylation. After providing cofactor support based on pathway maps combined with symptoms and lab results, the patient improved where previous single measures had failed.

Summary

I frequently use FGA for myself, my family, and the majority of my patients. I use it as a decision-support aid to generate hypotheses and enhance safety, never to replace diagnosis or clinical judgment. Used in this way, it makes my care more precise; and in at least one personal experience and several patient cases, it has also clearly improved safety. I am willing to speak directly with doctors or regulators who have questions about my experience.

Regards,
Morgan Clark Camp
MD · Functional and Integrative Medicine
Health Span Concierge · Licensed in California and Arizona
Sedona, Arizona, USA
July 9, 2026

Letter Two

The Ripple Effect of Functional Genomic Analysis™
How a framework helped me understand biology, restore hope, and help families get their lives back

Gail Rogers, DC · Certified Functional Genomic Analyst · Doctor of Chiropractic · Purdue University Engineer

DNA Optimal Health LLC · Licensed Doctor of Chiropractic in Idaho, USA · Specializing in Mold-Related Illness

From the Heart: Why I Wrote This Article

My son’s story—a disease that forever changed our entire family, led me to meet Bob Miller, and motivated me to become a functional genomic analyst.

There are moments in life that forever change the direction of our path. For me, that moment didn’t happen in a classroom, at a conference, or in a paper; it happened while I watched my teenage son gradually lose his vitality.

For eighteen months, our family lived through a nightmare familiar to many. One doctor after another said all tests were normal, yet we urgently searched for answers. We ran between specialists and hospitals, spending well over $100,000 trying every reasonable explanation, while watching the once-vibrant young man grow weaker and weaker, until he was ultimately bedridden. Sometimes he was too exhausted to speak; other times he didn’t even have the strength to go downstairs. More than once, I found him lying on the stair landing because he simply couldn’t go any further. As a mother, watching your child suffer without being able to help is the most heartbreaking thing.

Eventually, my son was correctly diagnosed with Lyme disease, and the infection was successfully treated, yet he remained severely ill, bedridden, and unable to participate in life. The infection was handled, but his body did not recover. That realization changed everything.

The doctor caring for my son suggested I contact Bob Miller for a Functional Genomic Analysis™. Bob’s office said appointments were booked six to ten weeks out. I couldn’t imagine waiting another month or two while my son continued to worsen. I sat in the Lyme doctor’s office expressing my despair, and a staff member gave me Bob’s personal email: “Email him; tell him the story of the most desperate mother.” I did, and Bob replied.

At the time, he had flown from the East Coast to the West Coast and had just finished a day of teaching. Even so, he called me to review my son’s Functional Genomic Analysis™ together. It was around 1:00 AM back on the East Coast. He could have been sleeping, but instead he chose to call a frightened mother he had never met and take the time to explain why my son might still be so weak.

Although I’m an engineer trained at Purdue University and hold a Doctor of Chiropractic degree, many of the terms were still beyond my understanding at the time. I didn’t grasp all the pathways and physiological mechanisms he described, but I understood the most important lines: “Do this.” “Stop that.” “And whatever you do, never do this.” Ironically, another practitioner—acting out of good intentions and following the standard protocol—had previously recommended exactly the intervention Bob advised against. That intervention caused my son’s condition to deteriorate sharply: his blood pressure dropped, and he lost another ten pounds, despite already being diagnosed with failure to thrive.

For the first time in months, someone looked beyond just Lyme disease and saw my son. The analysis identified potential patterns and biological vulnerabilities that helped explain why his body wasn't recovering. Based on this, Bob recommended personalized nutrition, dietary, and lifestyle support. Within about six weeks, my son's life changed dramatically: fatigue decreased, and strength returned. One afternoon, I watched him grab his skateboard to head downtown with friends. It was a remarkably ordinary moment that felt anything but ordinary to me. Our family had our son back.

When one person in a family is chronically ill, the whole family is affected. For eighteen months, we often couldn't take vacations or go to church as a family because someone always had to stay home with our son. Nearly every decision revolved around his illness. Now that our son is returning to a full life, so are we.

Shortly after our first consultation with Bob at 1:00 AM, my son suddenly broke out in terrible hives that spread to his neck, chest, and torso, like a thick purple carpet. I had never seen hives before and didn't know what was happening. I kept Bob's number handy and texted for help. He replied that he was speaking in Helsinki, Finland, and recognized for his research on Lyme disease; he would review my son's analysis after finishing his work a few hours later. About thirty minutes later, my phone rang again. Bob had reviewed the data and sent specific supplement protocols. Within fifteen minutes of taking them, the hives vanished completely. As a scientist and healthcare professional, I know there is a physiological explanation; as a mother, it felt miraculous.

It was then that I decided I wanted to learn how to help other families the way Bob helped us. My engineering education taught me to identify systems, patterns, and relationships; my chiropractic education taught me to appreciate the body's capacity to heal with the right support; motherhood taught me the importance of seeking answers. Functional Genomic Analysis™ bridges all these experiences. I became a Certified Functional Genomics Analyst.

I did not get to practice as a chiropractor before this. I met and married my husband during my studies; he reminded me that the hard-earned diploma doesn't dictate my life, and I have the freedom to choose my own path.

Note: Bob Miller has presented his research on genetics and chronic Lyme disease in Helsinki, Finland, through the International Lyme and Associated Diseases Society and has been recognized for his work. For more information, see the NutriGenetic Research Institute research archives: nutrigeneticresearch.org/research

Original Table of Contents

Part One: The Discovery of Functional Genomic Analysis™: 1 Why I Believe in It; 2 How It Differs; 3 What I Have Learned Along the Way.

Part Two What Functional Genomic Analysis™ Taught Me: We are not determined by a single gene; Focus on the person, not just the lab values; The analysis suggests questions worth asking; The body is usually trying to protect itself; It can often generate what it needs better than external intake; Look for patterns; Support biology in the correct order.

Part Three Families That Give Me Life Force: Family Case 1: The husband who just wanted his gentle wife back; 2: The mother who never gave up on saving her daughter; 3: The mother who felt herself fading away day by day; 4: The teacher who became my mentor; 5: The girl who finally walked onto a university campus; 6: The mother who never gave up on her dreams; 7: The cyclist who thought his life was over; 8: The seventy-year-old who taught me perseverance; 9: The lady who taught me patience; 10: The young man who showed me that hope can be regained.

Letter Three

Professional Experience Using Functional Genomic Analysis (FGA)

Anne Kelly, MD, MPH, CFMP · Medical Director, Holland Biomedical Clinic · Wazata, Minnesota, USA

For more than thirty years, I have cared for children and adults with complex chronic conditions, including autism spectrum disorder, attention-deficit/hyperactivity disorder, anxiety, chronic gastrointestinal disorders, autoimmune disease, mitochondrial dysfunction, chronic fatigue, neuroinflammation, and cognitive decline. Many of these patients have already seen multiple specialists and undergone extensive testing before seeking functional medicine care, because conventional approaches have not adequately explained or resolved their symptoms.

One of the most valuable tools I use in my practice is the Functional Genomic Analysis (FGA) developed by Robert (“Bob”) Miller and the NutriGenetic Research Institute. I am pleased to have the opportunity to share my professional experience using this platform.

What FGA Is—And Is Not

FGA is not a diagnostic test. It cannot replace clinical judgment, laboratory evaluation, imaging, or evidence-based medical decision-making. FGA is a more granular clinical decision support system that organizes a patient's raw genetic data into interrelated biochemical pathways. It helps clinicians identify patterns of genetic predisposition that may influence metabolism, detoxification, mitochondrial function, neurotransmitter balance, inflammation, immune regulation, antioxidant capacity, and nutritional needs, rather than examining one genetic variant at a time.

Like other tools I use in clinical practice, FGA generates hypotheses, not diagnoses. These hypotheses must always be interpreted in the context of a patient's medical history, physical examination, laboratory findings, and clinical response.

Why This Approach Matters

Many patients carry dozens of common genetic variants, each of which may have a minor individual effect. However, when multiple variants converge within the same biochemical pathway, their cumulative impact can become clinically significant. Traditional genetic reports often list hundreds of variants without providing a practical framework for understanding how these variants interact. FGA organizes variants into functional networks corresponding to intracellular biological processes.

Modern medicine has recognized that genetic variants can affect enzyme activity, nutrient metabolism, drug metabolism, detoxification, immune regulation, and susceptibility to disease. For example:

• CAT deficiency and susceptibility to oxidative stress
• MTHFR variants affecting folate metabolism
• BH4 metabolism affecting neurotransmitter synthesis and nitric oxide production
• SLC22A5 variants affecting carnitine transport
• Variants affecting glutathione production, antioxidant defense, bile acid metabolism, and mitochondrial function

How FGA Impacts My Clinical Practice

After incorporating FGA into clinical practice, my ability to identify underlying factors in complex conditions has improved markedly. In particular, among patients with autism, neurodevelopmental disorders, chronic fatigue, neuroimmune conditions, and treatment-resistant symptoms, the software frequently points to biochemical pathways warranting further laboratory evaluation or therapeutic consideration, such as:

• Impaired mitochondrial energy production
• Methylation and folate metabolism disturbances
• Oxidative stress
• Glutathione depletion
• Nitric oxide dysregulation
• Bile acid dysfunction
• Impaired fatty acid metabolism
• Ammonia metabolism
• Neurotransmitter synthesis
• Chronic inflammatory signaling
• Susceptibility to environmental toxins

Each recommendation should be supported or refuted through objective laboratory testing, prudent clinical evaluation, and ongoing monitoring of patient outcomes

Clinical Value

A key strength of FGA is that it helps enhance patient safety. The software frequently identifies certain genetic susceptibilities, prompting me to be more cautious before initiating treatments such as hyperbaric oxygen therapy. For example:

• Identifying G6PD deficiency prior to intravenous vitamin C infusion
• Risk of iron overload associated with HFE variants
• Impairment of detoxification pathways
• Altered nutritional requirements
• Increased susceptibility to oxidative damage

FGA tends to encourage a more prudent, personalized approach to care rather than promoting aggressive treatment. This is exactly how precision medicine should be practiced.

Educational Value

I also place high value on the continuing education offered by the NutriGenetic Research Institute. The biweekly practitioner webinars promote critical thinking rather than passive acceptance. Emerging concepts are consistently presented as hypotheses rather than established facts. Participants openly discuss supporting evidence, conflicting data, clinical observations, and unresolved questions. This collaborative environment continuously expands my understanding of nutritional biochemistry, mitochondrial medicine, environmental toxicology, neuroimmunology, and systems biology.

My Understanding of Bob Miller

Over the years, I have come to appreciate Bob Miller’s unique ability to integrate complex scientific disciplines into clinically practical frameworks. His strength lies in recognizing how multiple subtle disruptions in interconnected biochemical pathways interact, rather than viewing each pathway in isolation.

Looking back at the history of medicine, many advances began as carefully reasoned hypotheses that were later confirmed through research. The appropriate response is not to dismiss new ideas outright, but to engage in critical evaluation, careful testing, and revision of our understanding as new evidence emerges.

My Overall Assessment

After using functional genomic analysis extensively in clinical practice, I consider it a valuable adjunct to functional medicine and precision medicine. It has helped me better understand the clinical presentations of complex patients, identify potential biochemical factors that might otherwise be overlooked, develop more targeted treatment plans, and enhance patient safety.

Genetic factors alone never determine health outcomes. Environmental exposures, nutrition, infections, lifestyle, medications, toxic burden, epigenetics, and countless other variables all influence disease expression. FGA should never replace careful medical evaluation. However, when used responsibly, it provides a well-organized framework for incorporating genomic information into clinical decision-making.

As physicians continue to advance toward precision medicine, I believe tools that help clinicians understand complex biological systems while maintaining rigorous clinical judgment will become increasingly important. Based on my own experience caring for patients with complex chronic conditions, FGA has become one of the most valuable decision-support tools I use in my practice.

Anne Kelly, MD, MPH, CFMP
Medical Director · Holland Biomedical Clinic
Wasatta, Minnesota, USA

Letter Four

On the Scientific Research Foundation of Functional Genomic Analysis (FGA)

Harold Landis, DDS · Integrative Medicine Researcher · Collaborator in Functional Genomic Analysis Research

To Whom It May Concern:

As a researcher deeply involved in the study of the genetic and biochemical foundations of Functional Genomic Analysis (FGA), I write to directly respond to the baseless and hostile accusations directed at this software and its founder, Bob Miller. Whether in the intellectual or clinical realms, groundbreaking advances that challenge old paradigms always encounter fierce resistance from those who do not understand the science or who view innovation as a competitive threat. As Winston Churchill said, "Truth is undefeated. Malice can attack it, ignorance can mock it, but in the end, truth remains."

The criticism directed at this platform and Bob Miller does not stem from rigorous scientific evaluation but rather reveals a profound ignorance of advanced systems biology and modern translational genomics. This article aims to clarify the objective, evidence-based foundation of FGA as an important adjunct tool in modern healthcare.

I. Unparalleled Scientific Principles and Structural Hierarchy

Traditional genetic reporting platforms are fundamentally flawed and clinically outdated because they evaluate single nucleotide polymorphisms (SNPs) in complete isolation. Human biology does not operate in isolation. Built on rigorous systems biology principles, FGA mathematically models how complex genetic pathways intersect, overlap, or compensate; making it unique in the market.

To translate complex biochemistry into clear, actionable clinical decisions, FGA employs a refined and indispensable structural framework:

• Over 40 detailed pathway diagrams: The software contains over 40 distinct multi-dimensional pathway maps, visually tracing the flow of nutrients, cofactors, and metabolic blocks caused by genetic factors through complex cellular processes.
• The Pyramid System: This rigorous organizational hierarchy provides a clear, visual workflow, prompting practitioners to prioritize and support foundational pathways first, reducing the dangerous guesswork of blindly treating downstream imbalances.
• Executive Report: This interface is designed for high-level medical professionals, transforming complex genetic interactions into concise, information-dense summaries that help clinicians make rapid treatment decisions without sacrificing analytical depth.

Instead of generating a disconnected list of variants, FGA simulates true metabolic vulnerabilities. To bridge the gap between analysis and action, Bob Miller has designed personalized nutritional formulations targeting key high-priority SNPs, providing clinicians with immediate, precise, and exclusive intervention pathways.

II. Empirical Validation: Case Studies and Pathway Analysis

In my research and clinical work focused on translational genomics, I frequently use FGA to identify complex root causes of chronic diseases that standard diagnostic patterns may miss. The software's predictive power is demonstrated by our deep analysis of advanced cellular mechanisms and cross-pathways:

• Mitochondrial Decoupling, MAM Regions, and Cardiolipin Degradation: Our current research focuses on critical structures within the mitochondria and Mitochondria-Associated Endoplasmic Reticulum Membranes (MAM). FGA maps how environmental factors—specifically spike proteins, Lyme disease, and mycotoxins—trigger severe intracellular oxidative stress. This stress drives the cleavage and degradation of cardiolipin, a crucial phospholipid that anchors the inner mitochondrial membrane. When cardiolipin is compromised, the structural integrity of the Electron Transport Chain (ETC) supercomplexes collapses. The structural degradation of Complexes I through V undermines cellular ATP production and lipid homeostasis, forming the biochemical basis for chronic fatigue, neurodegenerative diseases, and various neurological disorders of unknown etiology.
• The Paradoxical Shift of GABA / Glutamate (NKCC1 and KCC2): FGA details the formation and protection of cell membranes, with a particular focus on the delicate relationship between the chloride co-transporters NKCC1 and KCC2. Genetic variations or environmental stressors affecting these transporters can disrupt intracellular chloride gradients, causing GABA—a neurotransmitter that is typically inhibitory and sedative—to paradoxically become an excitatory signal, while triggering neurotoxic glutamate signaling. Without FGA's visual mapping, clinicians treating anxiety or neuroinflammation might blindly use GABA agonists, potentially exacerbating the patient's neurological distress.
• The Intersection of Mast Cell Activation and Ferroptosis: By mapping genetic vulnerabilities in iron regulation, lipid peroxidation, and intracellular signaling, FGA helps us identify how iron-mediated cell death (ferroptosis) drives chronic, refractory Mast Cell Activation Syndrome (MCAS) in patients where conventional drug options have been exhausted.
• Tetrahydrobiopterin (BH4) Deficiency — A Pediatric Case: We analyzed a 12-year-old patient presenting with severe, unexplained neurotransmitter deficiency. FGA revealed that this child carries significant SNPs in three distinct biochemical pathways responsible for BH4 generation and recycling. Since BH4 is a necessary cofactor for synthesizing serotonin, dopamine, epinephrine, and norepinephrine, this comprehensive genetic bottleneck resulted in a severe systemic neurotransmitter deficit. The author believes that without FGA's pathway mapping and pyramid system, it would have been clinically difficult to detect the simultaneous disruption of these three pathways. By identifying these links, targeted nutritional interventions bypassed the blockages and led to a significant, life-changing clinical recovery.

3. Clinical Value as a Healthcare Assistive Tool

FGA does not replace traditional medicine; rather, it is a predictive adjunct. Modern medicine excels at acute crisis management and symptom control but often struggles with chronic, multi-systemic conditions of unknown etiology. FGA provides practitioners with a molecular roadmap. By understanding a patient's unique genetic architecture, practitioners can employ targeted nutritional and lifestyle interventions to optimize cellular function, improve patient outcomes, and alleviate the burden on traditional healthcare systems.

4. Continuous Evolution and Rigorous Education

This software is not a static tool but a database that continuously evolves with peer-reviewed literature. Our bi-weekly research webinars serve as an international high-level think tank, rigorously analyzing global genomic data, new biochemical insights, and clinical outcomes. Bob Miller's unwavering commitment to continuous research ensures that FGA remains at the forefront of translational genomics. Practitioners using this software receive continuous postgraduate education in system biology at a level and pace that exceeds standard coursework.

5. Bob Miller's Ability to Integrate Knowledge

Attacks on Bob Miller’s personal capabilities reflect a lack of professional ethics and an understanding of how genuine scientific innovation occurs. Innovation requires a rare ability to “connect the dots”: examining thousands of fragmented data points across immunology, toxicology, and biochemistry and synthesizing them into a coherent, actionable framework. Bob Miller possesses an extraordinary capacity for this multidimensional integration. His work successfully bridges raw genomic sequencing, targeted personalized nutritional supplementation, and practical clinical application. The author believes that the recovery of thousands of patients once deemed “incurable” by conventional medicine is a daily testament to his ability.

Conclusion

The author believes that the hostile attacks FGA faces in the international market are expected resistance faced by a disruptive technology challenging the status quo during its growth phase. While ignorance and malice may temporarily slow its adoption, they cannot alter the biochemical facts depicted by the software. The author believes that FGA is a tool with mathematical and scientific basis, representing the future of personalized preventive medicine.

Regards,
Harold Landis, DDS
Integrative medicine researcher · Collaborator in functional genomic analysis studies

Letter Five

My Professional Experience Using the FGA Platform

Ashok Tripathy, MD, ABFM, ABAARM · Family Medicine, Functional/Integrative Medicine · July 10, 2026

To Whom It May Concern:
Subject: Functional Genomic Analysis (FGA) — My Use of the FGA Platform and My Professional Experience with the Work of Founder Robert (Bob) Miller (CTN)

I am a family medicine physician with more than 35 years in practice, and I also practice integrative/functional medicine using a systems biology approach. I believe an individual’s genetic makeup and biochemical uniqueness are among the reasons they may be prone to chronic disease. I have used Functional Genomic Analysis (FGA) software for over five years. For the care of complex cases, it is an extremely valuable clinical support tool.

I am writing to support FGA and its founder, Bob Miller (CTN). As a primary care physician, I treat patients with chronic illness. These patients have sought care from various doctors—including specialists—and received treatment targeted at persistent symptoms, but no one has deeply understood their genetic makeup and biochemical uniqueness—in adults or children—factors that may explain why they are prone to chronic disease.

FGA provides me with such a tool to help patients. It applies modern translational genomics with a solid scientific foundation, using a systems biology approach to understand and formulate nutritional supplements that support individuals with genomic abnormalities or functional deficiencies. An individual’s SNP (single nucleotide polymorphism) or mutation may enhance function or diminish it. Therefore, the platform adopts a framework that includes the “Pyramid System,” multiple pathway maps (35 to 40 or more), and a concise “Action Report / Summary,” making it easy for busy clinicians to interpret and for patients to understand.

The various genetic susceptibilities brought about by mutations (SNPs) may increase the tendency toward illness at the functional level; when improving health and reducing symptoms, this information should be used as supporting evidence. Examples include SNPs related to inflammation, oxidative stress, free radicals (hydroxyl radical, superoxide anion, peroxynitrite, etc.), iron overload, calcium overload, histamine overload, nutritional abnormalities affecting enzyme cofactors (deficiency or excess), mitochondrial damage, electron transport chain (ETC) issues, and cell wall formation or destruction. The subsequent impact of these factors on optimizing health cannot be underestimated.

For my chronically ill patients, understanding their genetic tendencies related to the mechanisms above helps me help them and enables me to view their symptoms from a broader perspective. Together with epigenetic factors and other triggers—such as environment, gut health, infections, and lifestyle—I can address patients’ concerns more objectively. FGA education is grounded in extensive scientific literature. The software and courses help us connect SNPs, functional enhancement or reduction, and feedback loops that drive disease progression. Founder Bob Miller (CTN) hosts webinars and teaches every two weeks; without these sessions, it would be difficult for me to understand and connect how various SNPs and functional changes contribute to health problems. As research advances, we continue to study these areas to better understand the genome from a functional perspective.

The following content in FGA helps me better understand patients’ conditions, thereby supporting and improving their health outcomes. I use it as a “clinical tool” in my medical toolkit to assist in patients’ care, not to replace it:

• Fenton reaction (ferrous ions reacting with hydrogen peroxide to produce highly reactive hydroxyl radicals)
• Free radical damage (superoxide anion, hydroxyl radical, peroxynitrite, etc.)
• Inflammatory cascade (TNF-α, NF-κB, NLRP3, IL-1β, IL-18, COX-1 and COX-2, prostaglandins, ALOX5, LTB4)
• CD33
• Hydrogen sulfide and its effects
• Sirtuin 1, 2, 3
• Uncoupling of nitric oxide synthase
• Tetrahydrobiopterin (BH4) deficiency—a cofactor needed for neurotransmitter production; pathways showing BH4 generation and recycling
• Iron–sulfur clusters
• Mitochondrial damage
• Electron transport chain (ETC) issues
• Lipid peroxidation
• Mast cell activation and ferroptosis (iron-mediated cell death driving mast cell activation)
• Paradoxical GABA/glutamate shift (NKCC1 and KCC2)

In summary, this is a support tool that has been very helpful in my clinical practice, aiding in the management of complex cases and improving individual health outcomes. The software continues to evolve as science and knowledge advance, and we keep learning through biweekly seminars. Bob Miller (CTN) is an excellent teacher, able to connect SNPs with their many pathways. I have always been very satisfied with the software and look forward to learning more as science progresses, through such clear knowledge delivery.

Ashok Tripathy, MD, ABFM, ABAARM
Family Medicine, Functional/Integrative Medicine
July 10, 2026